• Vaccines

Menactra Generic Name & Formulations

General Description

Neisseria meningitidis polysaccharides 4mcg each of Group A, C, Y, and W-135; per 0.5mL; (diphtheria toxoid conjugate); soln for IM inj; preservative-free.

How Supplied

Single-dose vials—5


Menactra Indications


Meningitis immunization.

Menactra Dosage and Administration

Adults and Children

<9mos: not recommended. Give by IM inj only in deltoid region. Primary vaccination: 9–23mos: 0.5mL given as 2-dose series three months apart; 2–55yrs: 0.5mL once. Booster vaccination: 15–55yrs: may give a single (0.5mL) dose for those at continued risk, if at least 4yrs have elapsed since the prior dose.

Menactra Contraindications


Severe allergic reaction to any previous meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine.

Menactra Boxed Warnings

Not Applicable

Menactra Warnings/Precautions


Have epinephrine inj (1:1000) available. History of Guillain-Barre syndrome. Immunosuppressed. Risk of syncope. Latex allergy. Adults >55yrs old. Pregnancy (Cat.C). Nursing mothers.

Menactra Pharmacokinetics

See Literature

Menactra Interactions


Immunosuppressants (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose steroids) may get suboptimal response. Concomitant vaccines: see full labeling.

Menactra Adverse Reactions

Adverse Reactions

Inj site reactions, headache, fatigue, malaise, arthralgia, vomiting, diarrhea, anorexia, chills, fever, rash, irritability, drowsiness; children: also, abnormal crying.

Menactra Clinical Trials

See Literature

Menactra Note


To register pregnant patients or to report adverse events call (800) 822-2463. Refer to for ACIP guidelines on vaccinating acutely ill patients.

Menactra Patient Counseling

See Literature